FDA-approved1,2Evidence: Smaller human trialsHormones

Pasireotide1

Also called Signifor1,2

Key takeaway

Pasireotide is a synthetic cyclic peptide of six amino acids that mimics somatostatin, and the active ingredient in Signifor.1,2 FDA approved Signifor in 2012 for adults with Cushing’s disease for whom pituitary surgery is not an option or has not worked.1,2 In a randomized trial of 162 patients comparing two treatment arms, 15% and 26% had normal urine cortisol at six months. The label warns that it commonly raises blood sugar.1

Pasireotide at a glance

What it isA cyclohexapeptide somatostatin analogue that binds several somatostatin receptor subtypes, including subtype 5, which corticotroph tumors in Cushing’s disease often over-express, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Signifor with an original approval date of December 14, 2012. The cited label has no boxed warning.1,2
Human evidenceOne Phase 3, multicenter, randomized trial in 162 patients with Cushing’s disease comparing two treatment arms over six months, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is pasireotide?

Pasireotide is a cyclohexapeptide, a ring of six amino acids, that acts like the hormone somatostatin, according to the label.1

In the United States it is the active ingredient of Signifor, from Recordati Rare Diseases, according to Drugs@FDA.2

How does pasireotide work?

The label states that pasireotide binds somatostatin receptors, and that the pituitary tumor cells that cause Cushing’s disease often over-express receptor subtype 5.1

The label states that treatment suppresses secretion of ACTH, the pituitary hormone that drives cortisol, which may lower cortisol levels, sometimes too far.1

What do human studies show?

The label describes a Phase 3, multicenter, randomized trial in 162 adults with Cushing’s disease, 83% of whom had persistent or recurrent disease after pituitary surgery, comparing two treatment arms of Signifor for six months.1

At six months, 15% and 26% of patients in the two groups had normal average urine cortisol without needing an increase, and 34% and 41% met a less strict measure of response, according to the label.1

The trial had no placebo group, and about two-thirds of randomized patients completed six months, according to the label.1

What the evidence base contains

  • Controlled human trial A Phase 3, multicenter, randomized trial in 162 patients with persistent, recurrent or newly diagnosed Cushing’s disease comparing two treatment arms over six months, without a placebo group, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is pasireotide FDA-approved?

Yes. Drugs@FDA lists Signifor, application NDA 200677, with an original approval date of December 14, 2012.2

The Signifor label cited here (DailyMed SPL version 20, published February 18, 2026) states that it is indicated for adults with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.1

The label has no boxed warning and lists no contraindications. Its warnings include low cortisol, high blood sugar and diabetes, slow heart rate and QT prolongation, and raised liver tests.1

Timeline

  1. FDA approves Signifor, according to Drugs@FDA.2
  2. DailyMed publishes the Signifor label version cited on this page.1

What is still unknown?

How it compares with no treatment or other medicines: the trial described in the label compared two treatment arms of pasireotide without a placebo group.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Pasireotide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Pasireotide are a bounded selection, not every registration or paper about Pasireotide. For the years before Pasireotide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Pasireotide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Pasireotide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Signifor for Cushing’s disease. A randomized trial of 162 patients comparing two treatment arms, described in the label, found normal urine cortisol in 15% to 26% at six months. The label warns of high blood sugar and diabetes.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Pasireotide?

FDA-approved as Signifor for Cushing’s disease. A randomized trial of 162 patients comparing two treatment arms, described in the label, found normal urine cortisol in 15% to 26% at six months. The label warns of high blood sugar and diabetes.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
15
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.↗Source date October 31, 2026
  2. Literature metadata · added November 15, 2026

    Pituitary acting drugs: cabergoline and pasireotide.↗Source date October 30, 2026
  3. Literature metadata · added November 15, 2026

    Pasireotide: a review of its use in Cushing's disease.↗Source date October 11, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Pasireotide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

63Selected dated records
65Connected citations
15Populated source years2012–2026
3/4Record lanes present

Registered human studies

Trial composition

29 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 2 17Phase 1 8Phase 3 3Phase 4 3
Status at observationCompleted 26Active, not recruiting 2Recruiting 2

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 29Review 13Research Support, Non-U.S. Gov't 7Randomized Controlled Trial 4Case Reports 3Clinical Trial, Phase I 3Clinical Trial, Phase II 3Multicenter Study 3Research Support, N.I.H., Extramural 3Clinical Trial 1Clinical Trial, Phase III 1Clinical Trial, Phase IV 1Letter 1Meta-Analysis 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
63

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 63 dated records

Research hub

Explore the Pasireotide evidence record

Open all 63 records →
63Dated records
3Evidence types
63Cited public sources
15Source years

Change ledger

Recently changed for Pasireotide

Open all 63 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00171730

PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
September 5, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00171951

PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
June 2, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00434148

PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide.

PeptideScanner change date
November 15, 2026
Cited source date
March 8, 2016
Evidence lane
Clinical trials

Official-source collections

Source records for Pasireotide

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.Pituitary · 2026 09 23
  2. Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.Frontiers in endocrinology · 2025 11 13
  3. Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.Journal of clinical medicine · 2025 04 18
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05928390Registry update September 17, 2026 · current at observation
  2. NCT06295952Registry update March 4, 2026 · current at observation
  3. NCT02713776Registry update December 19, 2025 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span October 17, 2012 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 63

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.↗

    PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Pituitary acting drugs: cabergoline and pasireotide.↗

    PubMed lists PMID 35670988 in Pituitary as Journal Article, Review, with publication-date metadata of 2022-06-07 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Pasireotide: a review of its use in Cushing's disease.↗

    PubMed lists PMID 23605695 in Drugs as Journal Article, Review, with publication-date metadata of 2013-05 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT05928390↗

    PeptideScanner retained ClinicalTrials.gov record NCT05928390 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  5. Literature metadata

    Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.↗

    PubMed lists PMID 38713182 in Endocrine-related cancer as Journal Article, Multicenter Study, with publication-date metadata of 2024-05-27 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.↗

    PubMed lists PMID 38577574 in Frontiers in endocrinology as Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-03-21 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT06295952↗

    PeptideScanner retained ClinicalTrials.gov record NCT06295952 at 2026-11-15T22:05:38.400Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  8. Literature metadata

    Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.↗

    PubMed lists PMID 23228667 in Diabetes & metabolism as Journal Article, Review, with publication-date metadata of 2012-12-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.↗

    PubMed lists PMID 27473537 in Drugs as Journal Article, Review, with publication-date metadata of 2016-09 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT02713776↗

    PeptideScanner retained ClinicalTrials.gov record NCT02713776 at 2026-11-15T22:05:38.400Z. Its registry update date was 2025-12-19, and PeptideScanner's reviewed identity mapping was pasireotide.↗

  11. Literature metadata

    Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.↗

    PubMed lists PMID 41323967 in Frontiers in endocrinology as Journal Article, with publication-date metadata of 2025-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.↗

    PubMed lists PMID 40283624 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-04-18 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    SIGNIFOR (pasireotide) injection · SPL version 20 · published 2026-02-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: SIGNIFOR (pasireotide diaspartate), NDA 200677 · original approval December 14, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026